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Summary
Background If carotid artery narrowing remains asymptomatic (ie, has caused no recent stroke or other neurological 
symptoms), successful carotid endarterectomy (CEA) reduces stroke incidence for some years. We assessed the long-
term eﬀ ects of successful CEA.
Methods Between 1993 and 2003, 3120 asymptomatic patients from 126 centres in 30 countries were allocated equally, 
by blinded minimised randomisation, to immediate CEA (median delay 1 month, IQR 0·3–2·5) or to indeﬁ nite 
deferral of any carotid procedure, and were followed up until death or for a median among survivors of 9 years 
(IQR 6–11). The primary outcomes were perioperative mortality and morbidity (death or stroke within 30 days) and 
non-perioperative stroke. Kaplan-Meier percentages and logrank p values are from intention-to-treat analyses. This 
study is registered, number ISRCTN26156392.
Findings 1560 patients were allocated immediate CEA versus 1560 allocated deferral of any carotid procedure. The 
proportions operated on while still asymptomatic were 89·7% versus 4·8% at 1 year (and 92·1% vs 16·5% at 5 years). 
Perioperative risk of stroke or death within 30 days was 3·0% (95% CI 2·4–3·9; 26 non-disabling strokes plus 
34 disabling or fatal perioperative events in 1979 CEAs). Excluding perioperative events and non-stroke mortality, stroke 
risks (immediate vs deferred CEA) were 4·1% versus 10·0% at 5 years (gain 5·9%, 95% CI 4·0–7·8) and 10·8% versus 
16·9% at 10 years (gain 6·1%, 2·7–9·4); ratio of stroke incidence rates 0·54, 95% CI 0·43–0·68, p<0·0001. 62 versus 104 
had a disabling or fatal stroke, and 37 versus 84 others had a non-disabling stroke. Combining perioperative events and 
strokes, net risks were 6·9% versus 10·9%  at 5 years (gain 4·1%, 2·0–6·2) and 13·4% versus 17·9% at 10 years (gain 
4·6%, 1·2–7·9). Medication was similar in both groups; throughout the study, most were on antithrombotic and 
antihypertensive therapy. Net beneﬁ ts were signiﬁ cant both for those on lipid-lowering therapy and for those not, and 
both for men and for women up to 75 years of age at entry (although not for older patients). 
Interpretation Successful CEA for asymptomatic patients younger than 75 years of age reduces 10-year stroke risks. 
Half this reduction is in disabling or fatal strokes. Net beneﬁ t in future patients will depend on their risks from 
unoperated carotid lesions (which will be reduced by medication), on future surgical risks (which might diﬀ er from 
those in trials), and on whether life expectancy exceeds 10 years.
Funding UK Medical Research Council, BUPA Foundation, Stroke Association.
Introduction 
Asymptomatic patients with substantial (eg, 60–90%) 
carotid artery narrowing but no recent neurological 
symptoms are at increased long-term risk of ischaemic 
stroke, especially in parts of the brain supplied by that 
artery (the ipsilateral carotid territory). Carotid 
endarterectomy (CEA) can remove the arterial narrowing, 
but the procedure itself causes some immediate risk of 
stroke or death. 
The ﬁ rst Asymptomatic Carotid Surgery Trial 1 
(ACST-1; study protocol on webappendix pp 12–35) 
randomly assigned patients during 1993–2003 to 
immediate CEA or deferral of any carotid artery 
procedure until a more deﬁ nite indication was thought 
to have arisen, and followed them up until 2006–08. 
In 2004, ACST-1 reported the medium-term beneﬁ ts of 
CEA during the ﬁ rst few years after randomisation.1 
(Earlier trials2,3 had shorter follow-up.) This Article 
describes the immediate hazards and 10-year beneﬁ ts 
of CEA, subdividing the beneﬁ ts by participants’ 
characteristics and medical treatment.
Methods 
Study design and patients 
In asymptomatic patients with substantial carotid artery 
narrowing, ACST-1 compared immediate CEA versus 
deferral. All other aspects of treatment were left to the 
clinician, but usually included long-term antithrombotic 
therapy, antihypertensive therapy, and, particularly in 
recent years, lipid-lowering therapy. Use of these 
medical treatments was recorded at randomisation and 
at yearly follow-up. 126 centres in 30 countries took 
See Online for webappendix
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part, each with a neurosurgeon or vascular surgeon 
(selected as previously described1) and an independent 
neurologist or stroke doctor. Ethics approval was 
obtained both internationally and at each centre, and all 
patients provided written informed consent. 
Patients were eligible if: (1) they had severe unilateral 
or bilateral carotid artery stenosis (generally carotid 
artery diameter reduction at least 60%, although there 
was no ﬁ xed minimum percentage); (2) this stenosis 
had not caused stroke, transient cerebral ischaemia, or 
any other relevant neurological symptoms in the past 
6 months; (3) no circumstance or condition precluded 
long-term follow-up; and (4) doctor and patient were 
both substantially uncertain whether to choose 
immediate CEA or deferral of any CEA. The use of the 
uncertainty principle to deﬁ ne ACST eligibility is fully 
described in the study protocol (webappendix pp 18 and 
36) and elsewhere.1,4
Randomisation and masking 
By use of minimised randomisation, the Clinical Trial 
Service Unit (CTSU; Oxford, UK) allocated patients 
equally to immediate CEA or deferral of any carotid 
surgery. Collaborating doctors telephoned or faxed the 
patients’ identiﬁ ers and characteristics to the CTSU. 
Once these data were entered the patient was irrevocably 
in the trial, and the CTSU computer then generated a 
random allocation. This method minimised trial-wide 
imbalances within groups of age, sex, and percent 
stenosis, but was not aﬀ ected by the collaborating doctor’s 
location, so no foreknowledge of the treatment allocation 
was possible. When deﬁ nite or probable strokes were 
reported, the London trial oﬃ  ce sought medical records 
(or death records) through collaborating doctors for 
blinded review by the endpoints committee. There was 
no prespeciﬁ ed data analysis plan (except that the 
protocol-speciﬁ ed aim was to improve stroke-free survival 
time; webappendix p 14). 
Procedures 
Carotid artery stenosis was recorded as percentage 
luminal diameter reduction (assessed with duplex 
Doppler ultrasound by local criteria, which were 
generally as deﬁ ned by the North American Symptomatic 
Carotid Endarterectomy Trial [NASCET3]), and was 
usually rounded to 60%, 70%, 80%, or 90%. Plaque 
echolucency was recorded in some patients. During the 
ﬁ rst few years some also had angiography, but this 
procedure was not a requirement. 
CEA was to be done as soon as routinely possible. 
Surgeons’ normal operative techniques were used; 
shunting during surgery to maintain perfusion was 
optional, and anaesthetic technique was decided locally. 
Patients allocated deferral were not to be treated unless 
they later developed carotid territory symptoms or some 
other indication for surgery (or unless the doctor or 
patient changed their mind). Both groups were to 
receive appropriate medical care. Postoperatively, 
patients were assessed before discharge by the 
independent neurologist or stroke doctor. Tests for 
silent myocardial infarction were not routinely done. 
Follow-up was scheduled at 4 months and 12 months, 
and then yearly until 2006–08, irrespective of any non-
fatal strokes. It used forms completed by local doctors 
for the ﬁ rst 5 years after randomisation, then forms 
completed centrally from telephone contact with them. 
Both forms recorded any CEAs, their perioperative 
morbidity, any strokes or deaths, blood pressure, and 
current drug treatment (drug type, but not drug name 
or dose). Yearly carotid ultrasound was requested for 
only the ﬁ rst 5 years after randomisation. UK patients 
were ﬂ agged with the Oﬃ  ce of National Statistics, so 
death certiﬁ cates came automatically; elsewhere, 
mortality reporting was mainly through collaborating 
hospitals. Enquiries were made about all patients who 
died to ensure that no strokes had been missed.
Outcome classiﬁ cation 
The primary outcomes were perioperative mortality and 
morbidity (death or stroke within 30 days) and non-
perioperative stroke. Copies of post-mortems and brain 
scan reports were requested centrally from collaborators. 
The event summary, masked to treatment allocation 
(even for perioperative events), was sent to the endpoint 
review committee chair and one other member; 
disagreements were resolved by discussion. Strokes 
were classiﬁ ed according to location (ipsilateral, 
contralateral, vertebrobasilar), cause (haemorrhagic, 
probably cardio embolic, other ischaemic [not only large 
artery but also lacunar, as deﬁ ned in NASCET3]), and 
Figure 1: Trial proﬁ le
CEA=carotid endarterectomy. *Not 112, as was reported in 2004. 
3120 patients randomised, 1993–2003
1560 allocated to immediate CEA 
(median time to CEA 1·0 months [IQR 0·3–2·5])
1388 (89%) CEA within 1 year
172 no CEA within 1 year*
75 patient or doctor changed mind
76 medical or technical reasons at 
preoperative assessment
19 died without CEA (not stroke) 
within 1 year
2 stroke without CEA within 1 year  
At scheduled time for last clinic follow-up:
90 not traced within past 2 years 
(includes 34 not followed up to year 5)
52 moved
8 refused
3 follow-up stopped after the ﬁrst stroke
14 collaborator moved or died
13 collaborator refused after year 5
1560 allocated to deferral of any CEA
1445 (93%) no CEA within 1 year
115 CEA within 1 year + 292 CEA only later
47+114 patient or doctor changed mind
45+103 previous ipsilateral stroke 
(or transient cerebral ischaemia)
11+36 change in carotid lesion
8+30 non-carotid-related symptoms
4+9 with, or in preparation for, 
                                         cardiac surgery
At scheduled time for last clinic follow-up:
105 not traced within past 2 years 
(includes 36 not followed up to year 5)
53 moved
9 refused
3 follow-up stopped after the ﬁrst stroke
17 collaborator moved or died
23 collaborator refused after year 5
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outcome after 6 months (non-disabling, disabling, 
fatal). Disability was Rankin score 3 or greater (at least 
moderate disability, needing help in daily aﬀ airs); if a 
patient died of another cause within 6 months, the 
endpoint committee estimated previous stroke disability 
from clinical records. Most analyses were of ﬁ rst strokes; 
analyses of worst strokes counted patients only once, 
and fatal strokes were those that caused death directly 
or indirectly (eg, via pulmonary embolism or 
pneumonia), irrespective of the delay between stroke 
and death. 
Statistical analysis 
Information is reported up to year 10, or previous loss to 
follow-up or death. Kaplan-Meier life-table methods5 
describe 5-year and 10-year stroke risks in all patients 
allocated immediate CEA (including the few who did not 
undergo it) and all allocated deferral (including those 
eventually operated on). Additionally, analyses are given 
of procedural risks in patients who actually underwent 
CEA, plus details of which strokes within the ﬁ rst year 
were in patients who had not undergone CEA. In ACST, 
as in other trials of hazardous surgery, early risk may be 
followed by later beneﬁ t, so the overall hazard ratio 
(immediate CEA vs deferral) will undergo gross 
ﬂ uctuation, being unfavourable during the ﬁ rst 
few months after entry (when most operations are being 
done) and favourable thereafter. Hence, when comparing 
life-tables that include early risk and later beneﬁ t, 
standard proportional-hazard methods (which assume 
no gross ﬂ uctuations in hazard ratios) are inappropriate. 
Some analyses, however, are restricted to non-
perioperative strokes, so log-rank p values and event rate 
ratios are appropriate.5 If the log-rank observed minus 
expected (O–E) has variance V, the stroke incidence rate 
ratio (RR) is calculated as exp([O–E]/V). 95% CIs are 
used for rate ratios and for binomial proportions.6 
This study is registered, number ISRCTN26156392.
Role of the funding source 
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. AH, EH, HP, and RP had full access 
to all the data in the study, and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results 
3120 patients entered the study between April, 1993, and 
July, 2003, with no signiﬁ cant diﬀ erences in baseline 
characteristics between those randomly allocated 
immediate CEA and deferral.1 Patients allocated 
immediate CEA underwent ipsilateral surgery within a 
median of 1 month (IQR 0·3–2·5; ﬁ gure 1) of 
randomisation. Of those allocated deferral, an average of 
about 4% per year underwent CEA over the next decade 
(ﬁ gure 2). Only about a third (148/407) of these operations 
were in patients who had had a new ipsilateral stroke or 
episode of transient cerebral ischaemia; the main other 
reason was that patients or doctors changed their minds, 
not that lesions changed (ﬁ gure 1). Follow-up to death or 
at least year 3 is now 98% complete (3062/3120), and 
median follow-up in survivors is 9 years (IQR 6–11). 
Of patients allocated deferral, 26% (407/1560) 
underwent CEA within 10 years (table). The life-table 
estimate suggests that about a third would eventually 
have done so, had they survived; by 5 years after 
randomisation, about 92% versus 16% of those still 
without symptoms would have undergone CEA 
(ﬁ gure 2 and table). Hence, the Kaplan-Meier estimates 
of the diﬀ erences in 10-year outcome between those 
allocated immediate CEA and those allocated deferral 
indicate the diﬀ erences in 10-year outcome that could be 
expected from operating before symptom onset on only 
about three-quarters (92% minus 16%) of patients 
allocated immediate CEA and on none of those 
allocated deferral. 
The perioperative hazards of CEA in patients allocated 
immediate CEA and in those allocated deferral did not 
diﬀ er signiﬁ cantly (overall risk 3·0% [60/1979], 95% CI 
2·4–3·9; table). There was no signiﬁ cant heterogeneity 
between perioperative hazards in subgroups of age, sex, 
or extent of stenosis (data not shown), but this apparent 
homogeneity is not particularly informative since there 
were only 60 such events. National audits based on 
Figure 2: Allocated and actual use of CEA
CEA=carotid endarterectomy.
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much larger numbers would yield more stable estimates 
of how perioperative hazards depend on patient (and 
operator) characteristics. 
Median follow-up among survivors was 9 years 
(IQR 6–11). Figure 3 shows 10-year results for all strokes, 
including perioperative events, and for non-perioperative 
strokes, excluding mortality from causes other than CEA 
or stroke. In ﬁ gure 3A the hazards of surgery are clearly 
seen, as are the subsequent beneﬁ ts of successful surgery, 
and the absolute net beneﬁ ts that are apparent by year 5 
are maintained to year 10. If all patients allocated 
immediate CEA had undergone it promptly and none of 
those allocated deferral had undergone CEA unless they 
had had a stroke or an episode of transient cerebral 
ischaemia, the overall diﬀ erences would, in expectation, 
have been slightly greater. Of the 99 patients allocated 
immediate CEA who had a non-perioperative stroke, 11 
had not yet been operated on when their ﬁ rst stroke 
occurred; some of these 11 strokes might have been 
avoided by immedi ate CEA.
Figure 3B ignores perioperative events, assessing the 
eﬀ ects of treatment allocation only on non-perioperative 
strokes. The non-perioperative stroke incidence rate 
during the ﬁ rst 5 years was approximately halved in 
patients allocated immediate CEA, and the absolute 
diﬀ erence in risk at year 5 was still apparent at year 10.
The ratio of non-perioperative stroke rates in patients 
allocated immediate CEA versus those allocated deferral 
was 0·54 (95% CI 0·43–0·68, p<0·0001), corresponding, 
on average, to a 46% reduction in the stroke incidence 
rate. In webappendix p 7 the result is subdivided by the 
outcome of the worst stroke, and by the territory and 
cause of the ﬁ rst stroke. More than half of the patients 
with stroke (166/287) died of or were disabled by stroke, 
and the proportional reduction in disabling or fatal 
stroke seemed to be similar to that for any stroke. For 
strokes of known laterality, the greatest absolute 
reduction was in ipsilateral strokes (38 vs 92 events, 
RR 0·43 [0·28–0·68], p<0·0001), but there was also a 
signiﬁ cant reduction in other strokes (39 vs 64 con-
tralateral and 11 vs 23 vertebrobasilar). The reduction in 
contralateral strokes was separately signiﬁ cant (p=0·01), 
was not attributable to any substantial diﬀ erence in the 
use of contralateral CEA, and was largely independent 
of previous contralateral carotid symptoms or patency. 
The small numbers of haemorrhagic and of probably 
cardioembolic strokes did not seem to be aﬀ ected by 
CEA (webappendix p 7). The main eﬀ ect, as expected, 
was on ischaemic stroke (43 vs 104, including seven vs 
24 classiﬁ ed as deﬁ nitely lacunar).
The absolute eﬀ ect of halving the background stroke 
rate depends on what that background rate would have 
been without surgery, which depends on what long-
term medical treatments are used. Figure 4 shows, by 
year, the proportions on various types of medical 
treatment (irrespective of whether patients were 
receiving those treatments when they entered the 
study). Long-term medical therapy did not diﬀ er 
signiﬁ cantly between the two groups (ﬁ gure 4). Use of 
antihypertensive drugs increased during the study, 
whereas diastolic blood pressure decreased (from 
84·0 mm Hg [SD 10] in 1995 to 77·5 mm Hg [SD 11] in 
2005). Antithrombotic drug use (mainly aspirin) was 
common throughout the study, but use of lipid-lowering 
drugs increased from less than 10% to more than 80% 
(ﬁ gure 4). Webappendix p 8 subdivides non-perioperative 
strokes not only by the randomly allocated surgical 
treatment but also by what long-term medical treatment 
the patient was receiving at the time of the stroke (ie, 
what treatment the patient was receiving at the last 
follow-up before the stroke). The stroke rate ratio (CEA 
vs not) seemed to be similar for patients on lipid-
lowering therapy and those not, but because the absolute 
Immediate CEA 
(n=1560)
Deferral of any 
CEA (n=1560)
Surgical compliance
Number of patients with 
any CEA
1425 (91·3%) 407 (26·1%)
Proportion with any CEA (%)*
Within 1 year 89·8% 7·5%
Within 5 years 92·4% 23·5%
Within 10 years 92·5% 34·1%
Proportion with non-symptomatic CEA (%)*
Within 1 year 89·7% 4·8%
Within 5 years 92·1% 16·5%
Within 10 years 92·2% 23·5%
Proportion with ipsilateral CEA (%)*
Within 1 year 88·9% 6·9%
Within 5 years 91·5% 21·3%
Within 10 years 91·6% 29·8%
Proportion with contralateral CEA (%)*
Within 1 year 2·9% 0·8%
Within 5 years 5·5% 4·0%
Within 10 years 7·7% 7·5%
Perioperative mortality and morbidity
Total number of CEAs† 1532 447
Stroke death 11 2
Cardiac death 5 0
Other death 1 1
Disabling stroke 9 5
Non-disabling stroke 18 8
Non-fatal myocardial 
infarction
10 1
Any perioperative stroke 
or death
44 16
% of total number of CEAs 
(95% CI)
2·9% (2·1–3·8) 3·6% (2·2–5·7)
This table includes only CEAs done within 10 years of randomisation. CEA=carotid 
endarterectomy *Kaplan-Meier time-dependent percentages; denominators at 
these times are shown in ﬁ gure 2. †Ipsilateral or contralateral (bilateral=two CEAs) 
ﬁ rst or subsequent CEAs.
Table: Surgical compliance, mortality, and morbidity
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stroke rates were lower in those on lipid-lowering 
therapy, the absolute diﬀ erence in the stroke incidence 
rate produced by allocation to immediate CEA was not 
as great (0·7 vs 1·3% per year [p<0·0001] for those 
currently on lipid-lowering therapy, and 1·8 vs 3·3% per 
year [p<0·0001] for those not; webappendix p 8). Figure 
5 shows the estimated eﬀ ects on 10-year outcome (in 
patients who do not die from other causes within the 
ﬁ rst 10 years), analysing stroke rates according to both 
the allocated surgical treatment and current lipid-
lowering therapy. The event rates in patients on lipid-
lowering therapy suggest somewhat lower perioperative 
risks and lower absolute beneﬁ ts, but still with a 
signiﬁ cant reduction in net risk at year 10 (ﬁ gure 5A). 
Webappendix p 9 further subdivides non-perioperative 
stroke rates by time since entry (white squares) and by 
patient characteristics at entry (black squares). As 
already noted, the main gains were during the ﬁ rst 
5 years after entry, but there was no evidence that these 
early gains were lost in later years. The other subgroup 
analyses do not provide good evidence that the 
proportional risk reductions depend on initial patient 
characteristics (webappendix p 9). That does not 
mean the proportional risk reductions really are all 
identical, only that there is no trustworthy evidence 
of heterogeneity. 
Consider, for example, the age-speciﬁ c eﬀ ects of 
treatment allocation. The protective eﬀ ects were 
signiﬁ cant both for men and for women younger than 
75 years of age at entry (ﬁ gure 6), but not for older 
patients (webappendix p 9). This apparent heterogeneity 
of eﬀ ect could, however, have been due mainly to 
chance. If it was, then the overall results (ﬁ gures 3 and 
5) might provide the best guide as to what to expect in 
men or women of any age, if mortality from causes 
other than stroke is ignored. At entry, however, the older 
patients were, on average, 78 years of age, so within 
10 years most of them would have died from causes 
other than stroke (webappendix p 11, which also shows 
that about 90% of all deaths in this study were not from 
stroke—indeed, there were almost ﬁ ve times as many 
deaths from other vascular diseases as from stroke). 
Thus, expected 10-year gains would be greatly curtailed 
by intercurrent mortality in older patients, and 
somewhat curtailed even in younger ones. 
Combining perioperative or stroke mortality and other 
mortality, the total number of deaths within 10 years 
was not signiﬁ cantly lower in patients allocated 
immediate CEA than in those allocated deferral of any 
CEA (17 vs three perioperative deaths [including 11 vs 
two from stroke], 39 vs 68 other stroke deaths [p=0·006], 
298 vs 267 other vascular deaths [p=0·15], 111 vs 101 
cancer deaths [p=0·44], and 145 vs 131 other deaths 
[p=0·33]; webappendix p 11). After year 10, there were a 
further three stroke deaths in each group and 48 versus 
54 other deaths.
Figure 3: 10-year risk of any 
stroke or perioperative death 
(A) and any non-
perioperative stroke (B) 
After year 10  there were no 
perioperative strokes and four 
immediate versus seven 
deferred ﬁ rst strokes. 
CEA=carotid endarterectomy. 
py=per year.
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An apparently greater proportional risk reduction was 
recorded in patients with high cholesterol, mainly because 
prerandomisation cholesterol seemed (perhaps by chance) 
to be inversely related to the stroke rate in those allocated 
immediate CEA (webappendix p 9), but this ﬁ nding was 
based on fairly small numbers of strokes. Among those 
allocated deferral, the patient characteristics recorded at 
entry (including age, sex, cholesterol, blood pressure, 
plaque echolucency, and extent of stenosis) seemed to be 
of remarkably little relevance to subsequent stroke rates 
(webappendix p 9), which depended only on whether they 
were currently on lipid-lowering therapy (ﬁ gure 5). 
Figure 4: Current use (at or 
after randomisation) of 
various medical treatments 
by year of follow-up and by 
original treatment allocation 
(to immediate or deferred 
CEA)
CEA=carotid endarterectomy. 
DBP=diastolic blood pressure.
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Figure 5: 10-year risks, by 
current lipid-lowering 
therapy (at or after 
randomisation)
CEA=carotid endarterectomy. 
py=per year.
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Figure 6: 10-year risks for 
men and women younger 
than 75 years of age 
(mean 66) at entry 
CEA=carotid endarterectomy. 
py=per year.
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Discussion 
ACST-1 recruited more than 3000 patients with severe 
carotid artery stenosis that had not yet caused symptoms, 
randomly allocated them to immediate CEA or to deferral 
of any carotid procedure, and followed them up for a 
median of 9 years, which is much longer than in any 
previous trial reports.1–3 CEA caused some risk of 
perioperative stroke or death, but allocation to immediate 
CEA almost halved the non-perioperative stroke rate over 
the next 10 years. The characteristics recorded at entry of 
the patients and their carotid lesions were of little 
relevance to subsequent stroke rates, or to the eﬀ ect of 
CEA. The eﬀ ect of CEA was only on ischaemic strokes 
(including lacunar strokes, but not cardioembolic 
strokes); although the main eﬀ ect was on ipsilateral 
stroke, contralateral stroke was also reduced, presumably 
through mechanisms involving the circle of Willis. 
During the trial, no diﬀ erences in medical management 
were recorded between the two treatment groups. Most 
patients were on long-term antihypertensive and 
antithrombotic therapy. The population not on such 
therapy was too small to study separately, but that is not 
an important limitation because these treatments are 
eﬀ ective and continue to be used widely. Nowadays, lipid-
lowering therapy is also used widely, but it was not in 
1993, when ACST-1 began. In ACST, the proportion of 
patients on lipid-lowering therapy rose from less than 
10% in 1993 to more than 80% when follow-up ended in 
2006–08. Both for patients on lipid-lowering therapy and 
for those not, allocation to immediate CEA roughly 
halved the non-perioperative stroke rate (webappendix 
pp 8 and 9). These two results are separately signiﬁ cant, 
and reinforce each other. However, because those on 
lipid-lowering therapy had lower stroke incidence rates, 
the absolute beneﬁ t from successful CEA is 
correspondingly smaller for them than for others 
(ﬁ gure 5). 
Appropriate generalisation of results from surgical 
trials to future practice is indirect, because trial results do 
not directly assess risks or beneﬁ ts for future patients. 
The procedural hazards in this trial (or in other particular 
case series) might well diﬀ er from the hazards of CEA in 
future non-trial circumstances. Assessment of CEA risks 
in routine surgical practice will need large-scale, long-
term audits that continue to monitor perioperative 
morbidity in many hospitals in many countries. Audits 
can, if large enough, relate the hazards to the 
characteristics of the patient or lesion. The present report 
of 60 perioperative events in fewer than 2000 individuals 
makes only a small contribution to this monitoring of 
hazards, and cannot assess reliably the dependence of 
risk on patient characteristics. We note, however, that the 
3% morbidity rate in this series is similar to that for both 
men and women in some audits.7,8 The suggestion that 
procedural risks might be lower for patients on lipid-
lowering therapy also needs to be conﬁ rmed in series 
much larger than ours.9–11 
Expected beneﬁ ts depend on the likelihood that an 
unoperated asymptomatic lesion will eventually cause a 
serious stroke, and this risk can be substantially reduced 
by long-term medication, thereby reducing the expected 
beneﬁ ts of surgery. These expected beneﬁ ts also depend 
on the likelihood of death from unrelated causes over the 
next 10 years (which, considered separately, do not 
depend signiﬁ cantly on treatment allocation but do 
depend strongly on age; webappendix p 11). For men and 
for women on moderately good long-term anti-
hypertensive, antithrombotic, and lipid-lowering drugs, 
the 10-year stroke rates in the absence of other causes of 
death might be about as in ﬁ gures 5A and 5B. If, however, 
there was more than a 50% chance of dying from other 
causes within 10 years (as for those who were older than 
75 years at entry to the study), this absolute 10-year beneﬁ t 
would be reduced by more than half, while leaving the 
surgical risk unchanged. Although good antihypertensive 
therapy would have further improved blood pressure 
control (ﬁ gure 4) and modern statin regimens can reduce 
occlusive vascular event rates by more than a third,12–14 
patients with tight carotid stenosis cannot have the risk 
from it completely abolished by medical treatment alone. 
Hence, successful surgery could still usefully add to the 
eﬀ ects of good medical therapy, especially in patients 
who would otherwise have more than 10 years of 
reasonable life expectancy.
Despite the increasing availability of newer methods, 
the duplex ultrasound techniques used in this trial are 
still representative of much current practice. The extent 
of stenosis indicated by them was, somewhat surprisingly, 
of little relevance to long-term stroke risk, either in this 
study or in the largest other such trial.2 Stenosis was 
recorded with strong digit preference, generally as 
60%, 70%, 80%, or 90% (with few values less than 60% 
and none greater than 99%). Although more moderate 
degrees of stenosis might, if untreated, also be associated 
with substantial hazard, ACST-1 did not study them. 
Factors associated with plaque rupture are incompletely 
understood; although moderately stenotic asymptomatic 
plaques can rupture, causing symptoms, they may 
remain unchanged for many years.15,16 Our measures of 
plaque echolucency were of little predictive value. Future 
non-invasive techniques might, however, establish more 
reliably which asymptomatic lesions are particularly 
risky, which could greatly improve patient selection for 
CEA (or for carotid stenting; CREST,17 SPACE-2,18 and 
ACST-219,20 are now comparing carotid stenting vs carotid 
surgery; see webappendix p 36). 
Calculations of the cost-eﬀ ectiveness of CEA and of the 
number of patients that need to be treated to avoid one 
stroke should consider separately patients with short life 
expectancy and those with more than 10 years of 
reasonable life expectancy, because the potential long-
term beneﬁ ts of CEA are sharply curtailed in those who 
have less than 10 years of life expectancy. Conversely, 
ﬁ gure 5A (reinforced by the results in other subgroups) 
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suggests that, in patients with eﬀ ective antihypertensive, 
antithrombotic, and lipid-lowering therapy and with little 
likelihood of death from other causes within 10 years, the 
absolute 10-year stroke reduction would be about 5%. If 
so, the number needed to treat to avoid one stroke would 
be about 20. Allowance for non-compliance might reduce 
this number to about 15 (because 92% rather than 100% 
underwent early CEA, and by year 5 about 16% of those 
allocated deferral had undergone elective CEA). 
Conversely, appropriate allowance for intercurrent 
mortality from unrelated causes would increase the 
number needed to treat, so in patients older than 75 years 
little net beneﬁ t might be expected. For otherwise healthy 
men and women younger than 75 years, however, the 
results from this trial suggest net beneﬁ t from CEA, as 
long as perioperative risks remain low.
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